SG11201803642WA - Bacteria-based protein delivery - Google Patents

Bacteria-based protein delivery

Info

Publication number
SG11201803642WA
SG11201803642WA SG11201803642WA SG11201803642WA SG11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA
Authority
SG
Singapore
Prior art keywords
international
basel
rule
november
domains
Prior art date
Application number
SG11201803642WA
Inventor
Simon Ittig
Marlise Amstutz
Christoph Kasper
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of SG11201803642WA publication Critical patent/SG11201803642WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 May 2017(26.05.2017) WIPOIPCT (10) International Publication Number WO 2017/085235 A1 (51) International Patent Classification: C12N15/70 (2006.01) C07K14/195 (2006.01) C12N15/74 (2006.01) CI2N15/62 (2006.01) C12N1/21 (2006.01) (21) International Application Number: PCT/EP2016/078087 (22) International Filing Date: (25) Filing Language: (26) Publication Language: 17 November 2016 (17.11.2016) English English (30) Priority Data: 15195493.0 19 November 2015 (19.11.2015) EP (71) Applicant: UNIVERSITAT BASEL [CH/CH]; Petersg- raben 35, 4001 Basel (CH). (72) Inventors: ITTIG, Simon; Turkheimerstr. 45, 4055 Basel (CH). AMSTUTZ, Marlise; Wittlingerstr. 140, 4058 Basel (CH). KASPER, Christoph; Ruttigerweg 4, 4600 Olten (CH). (74) Agent: SCHOELLHORN, Andreas; Austrasse 24, 4051 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) < IT) n oo n O (54) Title: BACTERIA-BASED PROTEIN DELIVERY (57) : The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of re peated domains of a heterologous protein or two or more domains of different heterologous proteins into eukaryotic cells.
SG11201803642WA 2015-11-19 2016-11-17 Bacteria-based protein delivery SG11201803642WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15195493 2015-11-19
PCT/EP2016/078087 WO2017085235A1 (en) 2015-11-19 2016-11-17 Bacteria-based protein delivery

Publications (1)

Publication Number Publication Date
SG11201803642WA true SG11201803642WA (en) 2018-06-28

Family

ID=54697465

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803642WA SG11201803642WA (en) 2015-11-19 2016-11-17 Bacteria-based protein delivery

Country Status (24)

Country Link
US (1) US11702663B2 (en)
EP (1) EP3377634B1 (en)
JP (1) JP6937752B2 (en)
KR (1) KR20180081798A (en)
CN (1) CN108884466B (en)
AU (1) AU2016355975B2 (en)
BR (1) BR112018009782A8 (en)
CA (1) CA3005380A1 (en)
CY (1) CY1123654T1 (en)
DK (1) DK3377634T3 (en)
EA (1) EA039922B1 (en)
ES (1) ES2830251T3 (en)
HK (1) HK1256138A1 (en)
HR (1) HRP20201792T1 (en)
HU (1) HUE051184T2 (en)
IL (1) IL259050B2 (en)
LT (1) LT3377634T (en)
PL (1) PL3377634T3 (en)
PT (1) PT3377634T (en)
RS (1) RS61046B1 (en)
SG (1) SG11201803642WA (en)
SI (1) SI3377634T1 (en)
WO (1) WO2017085235A1 (en)
ZA (1) ZA201803901B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10968446B2 (en) 2012-11-01 2021-04-06 Massachusetts Institute Of Technology Directed evolution of synthetic gene cluster
KR102648293B1 (en) 2014-05-21 2024-03-15 우니페르시테트 바젤 Bacteria-based protein delivery
KR102197507B1 (en) 2015-07-13 2020-12-31 피벗 바이오, 인크. Methods and compositions for improving plant traits
PT3377094T (en) 2015-11-19 2021-07-08 Univ Basel Virulence attenuated bacteria for treatment of malignant solid tumors
HUE055832T2 (en) 2016-12-20 2021-12-28 Univ Basel Virulence attenuated bacteria based protein delivery
CN114480463A (en) * 2020-10-26 2022-05-13 南京吉芮康生物科技研究院有限公司 Novel coronavirus vaccine antigen presentation system for attenuated salmonella secreting and expressing RBD structural domain protein and application thereof
AU2021370840A1 (en) * 2020-10-27 2023-06-22 T3 Pharmaceuticals Ag Bacteria based protein delivery
AU2022244124A1 (en) * 2021-03-25 2023-11-09 T3 Pharmaceuticals Ag Pharmaceutical combinations for treating cancer
CN117362451B (en) * 2023-12-04 2024-03-08 北京质肽生物医药科技有限公司 Fusion protein containing TEV protease, preparation method and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
WO2000002996A2 (en) * 1998-07-10 2000-01-20 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
WO2002026819A2 (en) 2000-09-26 2002-04-04 Roger Williams Hospital Recombinant bcg vaccines for the prevention and treatment of cancer
WO2002077249A2 (en) * 2001-03-26 2002-10-03 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
FR2862312B1 (en) * 2003-11-13 2006-02-17 Univ Grenoble 1 TOOL FOR TRANSFER AND PRODUCTION OF PROTEINS USING THE PSEUDOMONAS TYPE III SECRETION SYSTEM
EP1661912A1 (en) * 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
JP2009510169A (en) 2005-10-04 2009-03-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Method for stimulating an immune response using a bacterial antigen delivery system
WO2008019183A2 (en) * 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
JP5670875B2 (en) * 2008-03-17 2015-02-18 ウニベルジテーツクリニクム ミュンスター YopM as a biotherapeutic agent for immunomodulating cargo molecules delivery vehicles and inflammatory responses
WO2015042706A1 (en) * 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-4 receptor-binding fusion proteins and uses thereof
US10143743B2 (en) * 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
KR102648293B1 (en) * 2014-05-21 2024-03-15 우니페르시테트 바젤 Bacteria-based protein delivery
PT3377094T (en) 2015-11-19 2021-07-08 Univ Basel Virulence attenuated bacteria for treatment of malignant solid tumors
HUE055832T2 (en) 2016-12-20 2021-12-28 Univ Basel Virulence attenuated bacteria based protein delivery

Also Published As

Publication number Publication date
CN108884466A (en) 2018-11-23
AU2016355975B2 (en) 2022-12-08
HRP20201792T1 (en) 2020-12-25
HK1256138A1 (en) 2019-09-13
JP6937752B2 (en) 2021-09-22
CN108884466B (en) 2022-06-03
HUE051184T2 (en) 2021-03-01
PL3377634T3 (en) 2021-03-08
PT3377634T (en) 2020-11-16
SI3377634T1 (en) 2021-01-29
EA201890914A1 (en) 2018-12-28
US20190194670A1 (en) 2019-06-27
RS61046B1 (en) 2020-12-31
EP3377634A1 (en) 2018-09-26
WO2017085235A1 (en) 2017-05-26
AU2016355975A1 (en) 2018-05-10
BR112018009782A8 (en) 2019-02-26
LT3377634T (en) 2020-12-28
ZA201803901B (en) 2019-04-24
JP2019500027A (en) 2019-01-10
EP3377634B1 (en) 2020-08-12
IL259050A (en) 2018-07-31
CA3005380A1 (en) 2017-05-26
CY1123654T1 (en) 2022-03-24
KR20180081798A (en) 2018-07-17
US11702663B2 (en) 2023-07-18
EA039922B1 (en) 2022-03-28
DK3377634T3 (en) 2020-11-16
BR112018009782A2 (en) 2018-11-06
ES2830251T3 (en) 2021-06-03
IL259050B2 (en) 2024-03-01
IL259050B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
SG11201803642WA (en) Bacteria-based protein delivery
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201908540PA (en) Stable antibody formulation
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811432WA (en) Rna for cancer therapy
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201807912SA (en) Vaccine against rsv
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201909011PA (en) Niraparib compositions
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201407343XA (en) Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
SG11201408174UA (en) Antibody formulation
SG11201408051VA (en) Cho expression system
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity